OBJECTIVE: To evaluate the effects of a daily E2 (1 mg) plus drospirenone oral formulation
(2 mg) on glycoinsulinemic metabolism, lipid profile, and endothelial function in symptomatic …

Objective The effects of estetrol (E4), a natural fetal estrogen, combined with drospirenone
(DRSP) were evaluated on plasma levels of sex hormone-binding globulin (SHBG) …

This open‐label study investigated whether drospirenone, a novel progestin with
antimineralocorticoid properties, increases the risk for hyperkalemia in subjects with renal …

The aim of this open-label, multicenter, noncomparative study was to determine the efficacy,
safety and bleeding profile of a new low-dose, monophasic combined oral contraceptive …

Objectives Progestogen-only pills (POPs) are safer with respect to cardiovascular risks than
contraceptives containing estrogens. Despite the increased contraceptive efficacy of a …

Abstract Objectives Oral contraceptives (OCs) containing androgenic second and third
generation progestins decrease insulin sensitivity (SI). In this study we investigated whether …

BACKGROUND: This study was conducted to compare ovarian activity of an oral
contraceptive containing drospirenone (drsp) 3 mg plus ethinylestradiol (EE) 20 mcg …

OBJECTIVE: The oral contraceptive ethinylestradiol 0.03 mg/drospirenone 3 mg contains a
progestin component that differs from other oral contraceptives. Case reports and …

Objective: The purpose of this study was to assess the efficacy and safety of a new low-dose
oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg (EE 20μg/drsp …

Abstract Objectives The “International Active Surveillance Study of Women Taking Oral
Contraceptives” investigated the risks of short-and long-term use of an extended 24-day …